(Nasdaq: TVTX) today announced that on October 10, 2026, the Compensation Committee of its Board of Directors granted ...

In late September and early October 2026, Travere Therapeutics reported new FILSPARI® (sparsentan) data across IgA ...

The package includes 36,000 options at a $52.02 exercise price per share and 142,580 restricted stock units, vesting over ...

Travere Therapeutics has announced that Bradley L. Campbell will become President and Chief Executive Officer on December 1, 2026, succeeding Eric Dube, Ph.D., who has decided to step down after ...

(Nasdaq: TVTX) today announced that it will share nine new data presentations, including five oral presentations, at the ...

Chief Medical Officer, EVP-Research & Development at Travere Therapeutics, Inc., starting in 2026. Former positions include Director at Kidney Health Initiative from 2013 to 2018 and Global Head-Renal ...

This is a real growth story, and FILSPARI is now the only approved medicine in its younger indication. But I rate the shares a Hold at this price. The valuation has run ahead of the evidence: roughly ...

Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced that on September 10, 2026, the Compensation Committee of its Board of Directors granted inducement equity grants to 16 new employees, ...

Eric Dube, Ph.D., is stepping down as CEO of Travere Therapeutics to “focus on his health and family,” the Filspari maker said. (Travere Therapeutics) Eric Dube, Ph.D., the CEO who rebranded Travere ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

So the stock is attached to a real, maturing franchise. The question is what the mRNA platform is worth, and the honest ...